HBM Holdings Limited (02142) has announced that its wholly owned subsidiary, Nona Biosciences (Suzhou) Co., Ltd, has entered into a non-exclusive license agreement with Pfizer. The arrangement seeks to accelerate antibody discovery in multiple potential disease areas, granting Pfizer global rights to utilize Nona Biosciences’ proprietary HCAb platform to generate fully human heavy chain-only antibodies.

Under the terms of the agreement, Nona Biosciences will receive an upfront payment and may be eligible for regulatory, clinical, and commercial milestone payments. The collaboration could also extend to antibody discovery, development, and engineering, leveraging Nona Biosciences’ HCAb platform and advanced B-cell screening technologies.

According to the announcement, there is no guarantee that HBM Holdings Limited or its collaboration partners will successfully develop or ultimately market the product candidates involved. Shareholders and potential investors are advised to exercise due care when dealing in the company’s shares. The board is chaired by Dr. Jingsong Wang, and the announcement is dated November 19, 2025.